GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:00217822 | Skin | AK | glial cell development | 24/1910 | 116/18723 | 5.74e-04 | 5.11e-03 | 24 |
GO:00330026 | Skin | AK | muscle cell proliferation | 39/1910 | 248/18723 | 4.16e-03 | 2.44e-02 | 39 |
GO:00109273 | Skin | AK | cellular component assembly involved in morphogenesis | 20/1910 | 107/18723 | 5.45e-03 | 3.02e-02 | 20 |
GO:00316411 | Skin | AK | regulation of myelination | 11/1910 | 47/18723 | 6.62e-03 | 3.50e-02 | 11 |
GO:00352653 | Skin | AK | organ growth | 29/1910 | 178/18723 | 7.57e-03 | 3.86e-02 | 29 |
GO:006053717 | Skin | SCCIS | muscle tissue development | 43/919 | 403/18723 | 1.50e-06 | 8.89e-05 | 43 |
GO:004599514 | Skin | SCCIS | regulation of embryonic development | 13/919 | 64/18723 | 1.13e-05 | 3.91e-04 | 13 |
GO:000736914 | Skin | SCCIS | gastrulation | 24/919 | 185/18723 | 1.33e-05 | 4.40e-04 | 24 |
GO:001470616 | Skin | SCCIS | striated muscle tissue development | 38/919 | 384/18723 | 3.33e-05 | 8.88e-04 | 38 |
GO:002178211 | Skin | SCCIS | glial cell development | 16/919 | 116/18723 | 1.72e-04 | 3.35e-03 | 16 |
GO:004206314 | Skin | SCCIS | gliogenesis | 29/919 | 301/18723 | 4.28e-04 | 6.87e-03 | 29 |
GO:00487384 | Skin | SCCIS | cardiac muscle tissue development | 24/919 | 236/18723 | 6.06e-04 | 9.04e-03 | 24 |
GO:00350513 | Skin | SCCIS | cardiocyte differentiation | 18/919 | 156/18723 | 6.58e-04 | 9.61e-03 | 18 |
GO:001000112 | Skin | SCCIS | glial cell differentiation | 23/919 | 225/18723 | 7.26e-04 | 1.03e-02 | 23 |
GO:004255212 | Skin | SCCIS | myelination | 16/919 | 134/18723 | 8.87e-04 | 1.15e-02 | 16 |
GO:00987421 | Skin | SCCIS | cell-cell adhesion via plasma-membrane adhesion molecules | 26/919 | 273/18723 | 9.83e-04 | 1.23e-02 | 26 |
GO:000727212 | Skin | SCCIS | ensheathment of neurons | 16/919 | 136/18723 | 1.04e-03 | 1.28e-02 | 16 |
GO:000836612 | Skin | SCCIS | axon ensheathment | 16/919 | 136/18723 | 1.04e-03 | 1.28e-02 | 16 |
GO:005076714 | Skin | SCCIS | regulation of neurogenesis | 32/919 | 364/18723 | 1.08e-03 | 1.32e-02 | 32 |
GO:005196013 | Skin | SCCIS | regulation of nervous system development | 37/919 | 443/18723 | 1.18e-03 | 1.40e-02 | 37 |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
TENM4 | SNV | Missense_Mutation | | c.191N>A | p.Val64Glu | p.V64E | Q6N022 | protein_coding | tolerated_low_confidence(0.1) | probably_damaging(0.988) | TCGA-A1-A0SM-01 | Breast | breast invasive carcinoma | Male | >=65 | I/II | Unknown | Unknown | SD |
TENM4 | SNV | Missense_Mutation | | c.2228N>A | p.Thr743Asn | p.T743N | Q6N022 | protein_coding | tolerated(0.15) | benign(0.254) | TCGA-A2-A04V-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | cytoxan | PD |
TENM4 | SNV | Missense_Mutation | rs756075933 | c.5105N>A | p.Arg1702His | p.R1702H | Q6N022 | protein_coding | tolerated(0.14) | probably_damaging(0.991) | TCGA-A2-A0CM-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | adriamycin | PD |
TENM4 | SNV | Missense_Mutation | rs750647178 | c.1855A>G | p.Lys619Glu | p.K619E | Q6N022 | protein_coding | deleterious(0.01) | benign(0.187) | TCGA-A2-A1FW-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Chemotherapy | cytoxan | SD |
TENM4 | SNV | Missense_Mutation | | c.6389T>C | p.Ile2130Thr | p.I2130T | Q6N022 | protein_coding | deleterious(0) | probably_damaging(0.977) | TCGA-A2-A25B-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | taxotere | PD |
TENM4 | SNV | Missense_Mutation | | c.6748G>T | p.Asp2250Tyr | p.D2250Y | Q6N022 | protein_coding | deleterious(0) | probably_damaging(0.997) | TCGA-A8-A07R-01 | Breast | breast invasive carcinoma | Female | >=65 | III/IV | Ancillary | zoledronic | SD |
TENM4 | SNV | Missense_Mutation | rs750647178 | c.1855A>G | p.Lys619Glu | p.K619E | Q6N022 | protein_coding | deleterious(0.01) | benign(0.187) | TCGA-AC-A23H-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | PD |
TENM4 | SNV | Missense_Mutation | | c.6110C>A | p.Thr2037Lys | p.T2037K | Q6N022 | protein_coding | deleterious(0.02) | benign(0.103) | TCGA-AC-A2FE-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Chemotherapy | adriamycin | PD |
TENM4 | SNV | Missense_Mutation | novel | c.1456N>T | p.Pro486Ser | p.P486S | Q6N022 | protein_coding | deleterious(0) | probably_damaging(0.996) | TCGA-AN-A046-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
TENM4 | SNV | Missense_Mutation | rs750647178 | c.1855N>G | p.Lys619Glu | p.K619E | Q6N022 | protein_coding | deleterious(0.01) | benign(0.187) | TCGA-AR-A1AY-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unspecific | Doxorubicin | SD |